CN116056760A - {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途 - Google Patents
{2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途 Download PDFInfo
- Publication number
- CN116056760A CN116056760A CN202180056233.1A CN202180056233A CN116056760A CN 116056760 A CN116056760 A CN 116056760A CN 202180056233 A CN202180056233 A CN 202180056233A CN 116056760 A CN116056760 A CN 116056760A
- Authority
- CN
- China
- Prior art keywords
- crystalline form
- peaks
- xrpd pattern
- cyclohexyl
- degrees
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202511373032.0A CN121202809A (zh) | 2020-06-08 | 2021-06-07 | {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063035994P | 2020-06-08 | 2020-06-08 | |
| US63/035,994 | 2020-06-08 | ||
| PCT/US2021/036082 WO2021252309A1 (en) | 2020-06-08 | 2021-06-07 | Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202511373032.0A Division CN121202809A (zh) | 2020-06-08 | 2021-06-07 | {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116056760A true CN116056760A (zh) | 2023-05-02 |
Family
ID=78846441
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180056233.1A Pending CN116056760A (zh) | 2020-06-08 | 2021-06-07 | {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途 |
| CN202511373032.0A Pending CN121202809A (zh) | 2020-06-08 | 2021-06-07 | {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202511373032.0A Pending CN121202809A (zh) | 2020-06-08 | 2021-06-07 | {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4161639A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023530785A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230048501A (cg-RX-API-DMAC7.html) |
| CN (2) | CN116056760A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021289591A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3181665A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2022015524A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021252309A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3093025A1 (en) | 2018-06-12 | 2019-12-19 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| US12391658B2 (en) | 2020-02-18 | 2025-08-19 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| US12479808B2 (en) | 2020-06-08 | 2025-11-25 | Vtv Therapeutics Llc | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102906077A (zh) * | 2010-05-26 | 2013-01-30 | 转化技术制药公司 | 二甲双胍与葡萄糖激酶激活剂的联合使用以及包含二甲双胍和葡萄糖激酶激活剂的组合物 |
| CN105188676A (zh) * | 2013-03-04 | 2015-12-23 | Vtv治疗有限责任公司 | 包括葡糖激酶活化剂的固体组合物及其制备和使用方法 |
| US20160015638A1 (en) * | 2013-03-04 | 2016-01-21 | Vtv Therapeutics Llc | Stable glucokinase activator compositions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0506662B8 (pt) * | 2004-01-06 | 2021-05-25 | Novo Nordisk As | compostos ativadores de glucoquinase |
| IN2014DN09554A (cg-RX-API-DMAC7.html) * | 2012-05-17 | 2015-07-17 | Transtech Pharma Llc | |
| DK3556354T3 (da) * | 2016-12-15 | 2025-08-04 | Hua Medicine Shanghai Ltd | Oral fremstilling af en glucokinaseaktivator og fremgangsmåde til fremstilling deraf |
-
2021
- 2021-06-07 CA CA3181665A patent/CA3181665A1/en active Pending
- 2021-06-07 CN CN202180056233.1A patent/CN116056760A/zh active Pending
- 2021-06-07 WO PCT/US2021/036082 patent/WO2021252309A1/en not_active Ceased
- 2021-06-07 KR KR1020237000609A patent/KR20230048501A/ko active Pending
- 2021-06-07 EP EP21821691.9A patent/EP4161639A4/en active Pending
- 2021-06-07 JP JP2023519156A patent/JP2023530785A/ja active Pending
- 2021-06-07 MX MX2022015524A patent/MX2022015524A/es unknown
- 2021-06-07 CN CN202511373032.0A patent/CN121202809A/zh active Pending
- 2021-06-07 AU AU2021289591A patent/AU2021289591A1/en active Pending
-
2022
- 2022-12-06 MX MX2026000786A patent/MX2026000786A/es unknown
-
2026
- 2026-03-04 JP JP2026034319A patent/JP2026108667A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102906077A (zh) * | 2010-05-26 | 2013-01-30 | 转化技术制药公司 | 二甲双胍与葡萄糖激酶激活剂的联合使用以及包含二甲双胍和葡萄糖激酶激活剂的组合物 |
| CN105188676A (zh) * | 2013-03-04 | 2015-12-23 | Vtv治疗有限责任公司 | 包括葡糖激酶活化剂的固体组合物及其制备和使用方法 |
| US20160015638A1 (en) * | 2013-03-04 | 2016-01-21 | Vtv Therapeutics Llc | Stable glucokinase activator compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2026000786A (es) | 2026-03-02 |
| JP2026108667A (ja) | 2026-06-30 |
| US20230219910A1 (en) | 2023-07-13 |
| EP4161639A4 (en) | 2024-01-17 |
| AU2021289591A1 (en) | 2023-01-19 |
| MX2022015524A (es) | 2023-03-22 |
| CA3181665A1 (en) | 2021-12-16 |
| WO2021252309A1 (en) | 2021-12-16 |
| JP2023530785A (ja) | 2023-07-19 |
| EP4161639A1 (en) | 2023-04-12 |
| CN121202809A (zh) | 2025-12-26 |
| KR20230048501A (ko) | 2023-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110922407B (zh) | 苯甲酰氨基吡啶衍生物的晶型及其用途 | |
| CN112638904A (zh) | 2-(3,5-二氯-4-((5-异丙基-6-氧代-1,6-二氢哒嗪-3-基)氧基)苯基)-3,5-二氧代-2,3,4,5-四氢-1,2,4-三嗪-6-腈的固体形式 | |
| CN121202809A (zh) | {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途 | |
| EP4010322B1 (en) | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof | |
| JP5566907B2 (ja) | N−(tert−ブトキシカルボニル)−3−メチル−l−バリル−(4r)−4−((7−クロロ−4−メトキシ−1−イソキノリニル)オキシ)−n−((1r,2s)−1−((シクロプロピルスルホニル)カルバモイル)−2−ビニルシクロプロピル)−l−プロリンアミドの結晶フォーム | |
| CN116194442A (zh) | {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的盐或共晶体及其用途 | |
| TW202333676A (zh) | 吡唑並〔3,4-d〕嘧啶化合物之固體形式 | |
| CN118894894A (zh) | 新生霉素类似物与脯氨酸的共晶体形式 | |
| HK40131995A (en) | Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and uses thereof | |
| US12030886B2 (en) | Form of ponatinib | |
| US20220251091A1 (en) | Amorphous umbralisib monotosylate | |
| KR20220012222A (ko) | 방향족 화합물의 고체 형태 및 그 제조 방법 | |
| HK40119275A (en) | Co-crystal forms of a novobiocin analog and proline | |
| HK40112450A (en) | Solid forms of pyrazolo[3,4-d]pyrimidine compounds | |
| US20210032235A1 (en) | Crystalline forms of dasatinib | |
| US20210246159A1 (en) | Novel form of bardoxolone methyl | |
| US20220298158A1 (en) | Polymorph of venetoclax and method for preparing the polymorph | |
| EA052651B1 (ru) | ТВЕРДЫЕ ФОРМЫ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫХ СОЕДИНЕНИЙ | |
| HK40074778A (en) | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof | |
| HK40074778B (en) | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof | |
| CA3057716A1 (en) | Novel forms of afatinib dimaleate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230502 |